Yong S. Chang, PhD
Chief Scientific Officer
Yong joined Ring Therapeutics as Chief Scientific Officer in June 2021. He brings extensive experience leading research, preclinical development and translational teams, and has a track record of advancing a number of technology-driven, innovative candidates to the clinic. Prior to Ring, Yong served as SVP at KorroBio where he was responsible for all aspects of development, including target biology, translational sciences, CMC, preclinical and clinical development. Prior to KorroBio, he was at Intellia Therapeutics where he led the first systemically delivered CRISPR/Cas gene editing candidate to the clinic. Yong has over 25 years of preclinical and drug development experience from both large pharma and biotech at Aileron Therapeutics, MedImmune/AstraZeneca, Bayer and Roche. He was a post-doctoral research Fellow at Harvard Medical School/MGH and received his PhD in physiology and BS in biology from The Pennsylvania State University.